Skip to content
HowShorted

Emergent Biosolutions, Inc. short interest in 2021

In 2021, Emergent Biosolutions, Inc.'s disclosed short interest ran from 4.93% of shares outstanding on 15 Jan 2021 to 6.19% on 31 Dec 2021, a change of +1.26 percentage points. The year's high was 7.03% on 30 Apr 2021 and its low 3.02% on 15 Nov 2021, averaging 5.62% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.46 days on 31 Aug 2021. Full history: Emergent Biosolutions, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Emergent Biosolutions, Inc. in 2021

2021 in figures

Start of year
4.93% (15 Jan 2021)
End of year
6.19% (31 Dec 2021)
Change
+1.26 pp
High
7.03% (30 Apr 2021)
Low
3.02% (15 Nov 2021)
Average
5.62%
Highest days to cover
9.46 (31 Aug 2021)
SEC filings marked
9

Every report in 2021

Emergent Biosolutions, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20214.93%5.15results (8-K)
29 Jan 20214.49%5.54
12 Feb 20214.49%4.91
26 Feb 20214.66%3.31results (8-K), 10-K filed
15 Mar 20214.91%4.13
31 Mar 20214.88%5.28
15 Apr 20216.52%2.80
30 Apr 20217.03%3.63results (8-K), 10-Q filed
14 May 20216.00%5.21
28 May 20215.12%5.66
15 Jun 20215.55%4.13
30 Jun 20216.68%3.74
15 Jul 20216.99%8.46
30 Jul 20216.93%7.11results (8-K), 10-Q filed
13 Aug 20216.60%9.31
31 Aug 20216.20%9.46
15 Sep 20215.95%9.08
30 Sep 20216.08%6.86
15 Oct 20215.99%9.06
29 Oct 20215.68%8.17
15 Nov 20213.02%1.17results (8-K), 10-Q filed
30 Nov 20214.92%1.35
15 Dec 20215.10%3.27
31 Dec 20216.19%3.75

See also: Emergent Biosolutions, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.